Objective:To investigate the relationship between changes in total plasma bile acid (TBA) levels and the remission of non-alcoholic fatty liver disease (NAFLD) in patients with obesity after laparoscopic sleeve gastrectomy (LSG).Methods:A retrospective analysis was conducted on clinical data and follow-up information of 20 patients with obesity and NAFLD undergoing LSG in Beijing Shijitan Hospital between Mar to Jun 2022.Results:Postoperative weight loss was significant. Compared to preoperative values, the weight of 20 patients decreased [(115.92±16.13) kg vs. (78.20±7.77) kg, t=15.675, P<0.001]. The BMI also decreased [(40.66±5.18) kg/m2 vs. (27.43±2.22) kg/m2, t=13.230, P<0.001]. The fatty liver index and hepatic steatosis index decreased significantly [(96.34±5.23) vs. (27.96±20.36), t=16.829, P<0.001; (55.15±6.73) vs. (37.55±4.30), t=16.294, P<0.001]. Plasma TBA levels significantly increased [(7.06±2.80) vs. (12.27±3.79) μmol/L, P<0.001]. Indicators related to glucose, lipids, and liver function in patients significantly decreased. Conclusions:LSG can significantly reduce body weight in patients with obesity and NAFLD and improve NAFLD. LSG can increase plasma TBA levels, and the elevation in TBA levels is positively correlated with the degree of NAFLD remission.

Objective:To investigate the relationship between changes in total plasma bile acid (TBA) levels and the remission of non-alcoholic fatty liver disease (NAFLD) in patients with obesity after laparoscopic sleeve gastrectomy (LSG).Methods:A retrospective analysis was conducted on clinical data and follow-up information of 20 patients with obesity and NAFLD undergoing LSG in Beijing Shijitan Hospital between Mar to Jun 2022.Results:Postoperative weight loss was significant. Compared to preoperative values, the weight of 20 patients decreased [(115.92±16.13) kg vs. (78.20±7.77) kg, t=15.675, P<0.001]. The BMI also decreased [(40.66±5.18) kg/m2 vs. (27.43±2.22) kg/m2, t=13.230, P<0.001]. The fatty liver index and hepatic steatosis index decreased significantly [(96.34±5.23) vs. (27.96±20.36), t=16.829, P<0.001; (55.15±6.73) vs. (37.55±4.30), t=16.294, P<0.001]. Plasma TBA levels significantly increased [(7.06±2.80) vs. (12.27±3.79) μmol/L, P<0.001]. Indicators related to glucose, lipids, and liver function in patients significantly decreased. Conclusions:LSG can significantly reduce body weight in patients with obesity and NAFLD and improve NAFLD. LSG can increase plasma TBA levels, and the elevation in TBA levels is positively correlated with the degree of NAFLD remission.

Background::The effect of bariatric surgery on type 2 diabetes mellitus (T2DM) control can be assessed based on predictive models of T2DM remission. Various models have been externally verified internationally. However, long-term validated results after laparoscopic sleeve gastrectomy (LSG) surgery are lacking. The best model for the Chinese population is also unknown.Methods::We retrospectively analyzed Chinese population data 5 years after LSG at Beijing Shijitan Hospital in China between March 2009 and December 2016. The independent t-test, Mann–Whitney U test, and chi-squared test were used to compare characteristics between T2DM remission and non-remission groups. We evaluated the predictive efficacy of each model for longterm T2DM remission after LSG by calculating the area under the curve (AUC), sensitivity, specificity, Youden index, positive predictive value (PPV), negative predictive value (NPV), and predicted-to-observed ratio, and performed calibration using Hosmer–Lemeshow test for 11 prediction models. Results::We enrolled 108 patients, including 44 (40.7%) men, with a mean age of 35.5 years. The mean body mass index was 40.3 ± 9.1 kg/m 2, the percentage of excess weight loss (%EWL) was (75.9 ± 30.4)%, and the percentage of total weight loss (% TWL) was (29.1 ± 10.6)%. The mean glycated hemoglobin A1c (HbA1c) level was (7.3 ± 1.8)% preoperatively and decreased to (5.9 ± 1.0)% 5 years after LSG. The 5-year postoperative complete and partial remission rates of T2DM were 50.9% [55/108] and 27.8% [30/108], respectively. Six models, i.e., "ABCD", individualized metabolic surgery (IMS), advanced-DiaRem, DiaBetter, Dixon et al’s regression model, and Panunzi et al’s regression model, showed a good discrimination ability (all AUC >0.8). The "ABCD" (sensitivity, 74%; specificity, 80%; AUC, 0.82 [95% confidence interval [CI]: 0.74–0.89]), IMS (sensitivity, 78%; specificity, 84%; AUC, 0.82 [95% CI: 0.73–0.89]), and Panunzi et al’s regression models (sensitivity, 78%; specificity, 91%; AUC, 0.86 [95% CI: 0.78–0.92]) showed good discernibility. In the Hosmer–Lemeshow goodness-of-fit test, except for DiaRem ( P <0.01), DiaBetter ( P <0.01), Hayes et al ( P = 0.03), Park et al ( P = 0.02), and Ramos-Levi et al’s ( P <0.01) models, all models had a satifactory fit results ( P >0.05). The P values of calibration results of the "ABCD" and IMS were 0.07 and 0.14, respectively. The predicted-to-observed ratios of the "ABCD" and IMS were 0.87 and 0.89, respectively. Conclusion::The prediction model IMS was recommended for clinical use because of excellent predictive performance, good statistical test results, and simple and practical design features.